Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06375811 · ClinicalTrials.gov registry record · Phase 3
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
A Phase 3 study of Infertility and Endometriosis, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 297
- Enrollment target
- 5
- Study locations
NCT06375811 is a Phase 3 study of Infertility and Endometriosis that is actively recruiting participants, run by Yale University. The registered enrollment target is 297 participants, below the 7,585-participant average among 74 other Infertility trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT06375811, a Phase 3 study of Infertility and Endometriosis, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 297 participants
- Enrollment target
- 5
- Study locations
Study Summary
A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to those not pretreated with GnRH antagonist.
Conditions Studied
Interventions
- DRUG Elagolix 200 MG
- OTHER Placebo or SOC IVF
Study Locations (5)
Colorado
- University of Colorado Department of Obstetrics & Gynecology - Aurora
Connecticut
- Yale School of Medicine Dept.of Ob/Gyn & Reproductive Sciences - New Haven
Illinois
- Northwestern University Department of Obstetrics and Gynecology - Chicago
Maryland
- Johns Hopkins, Division of Reproductive Science and Women's Health Research - Baltimore
North Carolina
- Duke Fertility - Morrisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2024-03-16 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06375811
The ClinicalTrials.gov registry entry for NCT06375811 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 297 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,585-participant average among 74 other Infertility trials with a reported enrollment target (96% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Infertility appearing as the primary indexed condition, and to 2 interventions - of which Elagolix 200 MG is the first listed.
NCT06375811 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Colorado, Connecticut, Illinois.
Frequently Asked Questions
What is clinical trial NCT06375811 about?
NCT06375811 is a clinical study titled "Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp". A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET...
What is the current status of trial NCT06375811?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 297 participants. The study started on 2024-03-16. Estimated completion is 2026-09-30.
What conditions does trial NCT06375811 study?
This clinical trial studies the following conditions: Infertility, Endometriosis.
What interventions are being tested in trial NCT06375811?
The interventions under investigation include: Elagolix 200 MG (DRUG), Placebo or SOC IVF (OTHER).
Who is sponsoring clinical trial NCT06375811?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06375811 being conducted?
This trial has 5 study locations across Colorado, Connecticut, Illinois, Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infertility
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
RECRUITING · Phase 3
-
Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
ACTIVE NOT RECRUITING · Phase 3
-
Vaginal Culture Using INVOcell Compared to Traditional IVF Incubation
COMPLETED · Phase 3
-
Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)
COMPLETED · Phase 3
-
A Clinical Trial to Evaluate the Efficacy and Safety of DR-2011 for In Vitro Fertilization
COMPLETED · Phase 3
-
Gamete Treatment to Correct Fertilization Failure
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.